Pricing Log in Create free account
Saturday 17 October 2026 Export BVS’s income statement to Excel — free account

Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

13.30 0.51 −3.69%
Market cap
$1.2B
P/E
16.4×
Fwd P/E
21.4×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bioventus Inc. (BVS) Business Profile

Updated before January 2025

Company Overview

Bioventus Inc. (BVS) is a global leader in orthobiologics and advanced rehabilitation solutions, headquartered in Durham, North Carolina, USA. The company was founded in 2012 as a spin-off from Smith & Nephew, a multinational medical equipment manufacturing company. Bioventus focuses on developing and commercializing clinically proven, cost-effective products that help patients heal faster and regain mobility. The company operates with a mission to improve the lives of patients by delivering innovative medical solutions that enhance healing and mobility.

Key leadership at Bioventus includes its CEO, Ken Reali, who has extensive experience in the medical device and healthcare industries. Under his leadership, Bioventus has expanded its product portfolio and strengthened its position in the global market. The company is publicly traded on the NASDAQ under the ticker symbol “BVS.”

Core Business Segments

Bioventus operates across several core business segments, offering a diverse range of products and services aimed at improving patient outcomes. These segments include:

1. Orthobiologics

Bioventus is a leader in orthobiologics, which are biological products used to enhance the body’s natural healing processes. Key products in this category include:

  • EXOGEN® Ultrasound Bone Healing System: A non-invasive device that uses low-intensity pulsed ultrasound to stimulate bone healing in fractures.
  • OSTEOAMP®: A bone graft substitute used in spinal and orthopedic surgeries.
  • DUROLANE®: A single-injection hyaluronic acid therapy for treating osteoarthritis pain in joints.

2. Pain Treatments

Bioventus offers innovative solutions for managing chronic pain, particularly in patients with osteoarthritis. Products in this segment include:

  • GELSYN-3®: A three-injection hyaluronic acid therapy for knee osteoarthritis.
  • SUPARTZ FX®: A five-injection hyaluronic acid therapy for joint pain relief.

3. Surgical Solutions

The company provides advanced surgical solutions to support orthopedic and spinal procedures. Products in this category include:

  • SIGNIFY®: A bioactive bone graft substitute that promotes bone growth.
  • OSTEOAMP® Select: A next-generation bone graft solution for surgical applications.

4. Rehabilitation Solutions

Bioventus also offers rehabilitation products and services designed to help patients recover mobility and function after injuries or surgeries. These include physical therapy devices and support systems.

Business Model

Bioventus operates on a business model that integrates innovative products and services to address unmet medical needs. The company generates revenue through the sale of its medical devices, biologics, and rehabilitation solutions to healthcare providers, hospitals, and clinics worldwide. Bioventus also collaborates with healthcare professionals to ensure the effective use of its products, thereby improving patient outcomes.

The company invests heavily in research and development (R&D) to bring new and improved products to market. It also focuses on strategic partnerships and acquisitions to expand its product portfolio and market reach. Bioventus’s customer-centric approach and commitment to quality have helped it build strong relationships with healthcare providers and patients.

Strategic Direction

Bioventus has a clear strategic direction aimed at driving growth and innovation. Key elements of its strategy include:

  • Product Innovation: The company is committed to developing new products and improving existing ones to address evolving patient needs.
  • Market Expansion: Bioventus aims to expand its presence in emerging markets and strengthen its position in established markets.
  • Sustainability Goals: The company is focused on reducing its environmental footprint and promoting sustainable practices across its operations.
  • Digital Transformation: Bioventus is leveraging digital technologies to enhance its product offerings and improve customer engagement.

Competitive Landscape

Bioventus operates in a highly competitive market, facing competition from both established players and emerging companies. Key competitors include:

  • Zimmer Biomet: A global leader in musculoskeletal healthcare solutions.
  • Stryker Corporation: A leading medical technology company offering a wide range of orthopedic products.
  • Medtronic: A multinational medical device company with a strong presence in the orthobiologics market.
  • DePuy Synthes: A subsidiary of Johnson & Johnson, specializing in orthopedic and spinal solutions.

Despite the competition, Bioventus differentiates itself through its focus on innovation, quality, and customer-centric solutions.

Risk Factors

Bioventus faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily dependent on the sales of its core products, making it vulnerable to market fluctuations.
  • Regulatory Challenges: Bioventus operates in a highly regulated industry, and changes in regulations could affect its operations.
  • Supply Chain Disruptions: The company relies on a global supply chain, which could be disrupted by geopolitical events, natural disasters, or pandemics.
  • Competition: Intense competition in the medical device and orthobiologics markets could impact Bioventus’s market share and profitability.

Recent Developments

Bioventus has made significant strides in recent years, including:

  • Product Launches: The company has introduced new products, such as advanced bone graft solutions and pain management therapies.
  • Strategic Acquisitions: Bioventus has acquired several companies to expand its product portfolio and market reach.
  • Global Expansion: The company has entered new markets and strengthened its presence in existing ones.
  • Digital Initiatives: Bioventus has launched digital tools and platforms to enhance customer engagement and product accessibility.

Investment Considerations

Investors considering Bioventus should weigh the following strengths and risks:

Strengths

  • Strong product portfolio with clinically proven solutions.
  • Commitment to innovation and R&D.
  • Established presence in global markets.
  • Experienced leadership team.

Risks

  • Dependence on a few key products for revenue.
  • Exposure to regulatory and compliance risks.
  • Vulnerability to supply chain disruptions.
  • Intense competition in the industry.

Conclusion

Bioventus Inc. is a leading player in the orthobiologics and medical device industry, with a strong focus on innovation and patient-centric solutions. The company’s diverse product portfolio, strategic initiatives, and commitment to quality position it well for future growth. However, it must navigate challenges such as market dependence, regulatory risks, and competition to maintain its leadership position. Overall, Bioventus offers significant growth potential for investors and remains a key player in the global healthcare market.